Iovance Biotherapeutics Stock Analysis

Iovance Stock Analysis Notes

About 84.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iovance Biotherapeutics recorded a loss per share of 1.28. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 26th of September 2013. Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patients immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Iovance Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 319 people. To learn more about Iovance Biotherapeutics call Esq JD at (650) 260-7120 or check out https://www.iovance.com.

Iovance Biotherapeutics Investment Alerts

Iovance Biotherapeutics Upcoming and Recent Events

Iovance Largest EPS Surprises

View All Earnings Estimates

Iovance Biotherapeutics Environmental, Social, and Governance (ESG) Scores

Iovance Biotherapeutics Thematic Classifications

Iovance Stock Institutional Investors

Note, although Iovance Biotherapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Iovance Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.13 B.

Iovance Profitablity

The company has Profit Margin (PM) of (2.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.17) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.17.

Management Efficiency

Iovance Biotherapeutics has return on total asset (ROA) of (0.2922) % which means that it has lost $0.2922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5748) %, meaning that it created substantial loss on money invested by shareholders. Iovance Biotherapeutics' management efficiency ratios could be used to measure how well Iovance Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 27, 2025, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.53. At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 476.1 M, whereas Total Current Assets are forecasted to decline to about 235.4 M.

Technical Drivers

As of the 27th of March, Iovance Biotherapeutics retains the Standard Deviation of 4.12, market risk adjusted performance of (1.22), and Risk Adjusted Performance of (0.20). Iovance Biotherapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Iovance Biotherapeutics Price Movement Analysis

Iovance Biotherapeutics Insider Trading Activities

Iovance Biotherapeutics Outstanding Bonds

Iovance Biotherapeutics Predictive Daily Indicators

Iovance Biotherapeutics Corporate Filings

Iovance Biotherapeutics Forecast Models

Iovance Biotherapeutics' time-series forecasting models are one of many Iovance Biotherapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Iovance Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Iovance Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Iovance shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Iovance Biotherapeutics. By using and applying Iovance Stock analysis, traders can create a robust methodology for identifying Iovance entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Iovance analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Iovance analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Iovance Biotherapeutics stock analysis indicators help investors evaluate how Iovance Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Iovance Biotherapeutics shares will generate the highest return on investment. By understating and applying Iovance Biotherapeutics stock analysis, traders can identify Iovance Biotherapeutics position entry and exit signals to maximize returns.

When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.